198 related articles for article (PubMed ID: 35477569)
1. An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer.
Wang W; Wang J; Liu S; Ren Y; Wang J; Liu S; Cui W; Jia L; Tang X; Yang J; Wu C; Wang L
Mol Cancer; 2022 Apr; 21(1):106. PubMed ID: 35477569
[TBL] [Abstract][Full Text] [Related]
2. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
[TBL] [Abstract][Full Text] [Related]
3. Involvement of miR-4262 in paclitaxel resistance through the regulation of PTEN in non-small cell lung cancer.
Sun H; Zhou X; Bao Y; Xiong G; Cui Y; Zhou H
Open Biol; 2019 Jul; 9(7):180227. PubMed ID: 31337279
[TBL] [Abstract][Full Text] [Related]
4. Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.
Yang X; Zhao D; Li Y; Li Y; Cui W; Li Y; Li H; Li X; Wang D
Thorac Cancer; 2020 Oct; 11(10):2858-2866. PubMed ID: 32875729
[TBL] [Abstract][Full Text] [Related]
5. Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
Wang L; Dong X; Ren Y; Luo J; Liu P; Su D; Yang X
Cell Death Dis; 2018 Jan; 9(2):129. PubMed ID: 29374157
[TBL] [Abstract][Full Text] [Related]
6. Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors.
Wang NN; Wang LH; Li Y; Fu SY; Xue X; Jia LN; Yuan XZ; Wang YT; Tang X; Yang JY; Wu CF
Exp Cell Res; 2018 Jan; 362(1):72-82. PubMed ID: 29155365
[TBL] [Abstract][Full Text] [Related]
7. SOX2 regulates paclitaxel resistance of A549 non‑small cell lung cancer cells via promoting transcription of ClC‑3.
Huang Y; Wang X; Hu R; Pan G; Lin X
Oncol Rep; 2022 Oct; 48(4):. PubMed ID: 36069232
[TBL] [Abstract][Full Text] [Related]
8. EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Kim H; Choi SY; Lim J; Lindroth AM; Park YJ
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32028644
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption.
Wang Y; Zhou Y; Zheng Z; Li J; Yan Y; Wu W
Cell Death Dis; 2018 Nov; 9(11):1134. PubMed ID: 30429459
[TBL] [Abstract][Full Text] [Related]
10. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
11. EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer.
Yang C; Ma S; Zhang J; Han Y; Wan L; Zhou W; Dong X; Yang W; Chen Y; Gao L; Cui W; Jia L; Yang J; Wu C; Wang Q; Wang L
Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2317790121. PubMed ID: 38814866
[TBL] [Abstract][Full Text] [Related]
12. Circ_0011292 Enhances Paclitaxel Resistance in Non-Small Cell Lung Cancer by Regulating miR-379-5p/TRIM65 Axis.
Guo C; Wang H; Jiang H; Qiao L; Wang X
Cancer Biother Radiopharm; 2022 Mar; 37(2):84-95. PubMed ID: 32833503
[No Abstract] [Full Text] [Related]
13. Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer.
Niu X; Wu T; Yin Q; Gu X; Li G; Zhou C; Ma M; Su L; Tang S; Tian Y; Yang M; Cui H
Cells; 2022 Oct; 11(19):. PubMed ID: 36231056
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Elucidating Paclitaxel Resistance Mechanisms in Non-small Cell Lung Cancer and Strategies to Overcome Drug Resistance.
Cui H; Arnst K; Miller DD; Li W
Curr Med Chem; 2020; 27(39):6573-6595. PubMed ID: 33243106
[TBL] [Abstract][Full Text] [Related]
15. Metformin Suppresses Stemness of Non-Small-Cell Lung Cancer Induced by Paclitaxel through FOXO3a.
Tang Z; Zhang Y; Yu Z; Luo Z
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068934
[TBL] [Abstract][Full Text] [Related]
16. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance.
Zhang W; Shi Y; Chen Y; Yu S; Hao J; Luo J; Sha X; Fang X
Eur J Pharm Biopharm; 2010 Aug; 75(3):341-53. PubMed ID: 20451605
[TBL] [Abstract][Full Text] [Related]
17. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.
Chen S; Zhang Z; Zhang J
Drug Des Devel Ther; 2019; 13():1145-1153. PubMed ID: 31114158
[No Abstract] [Full Text] [Related]
18. Interleukin-22 (IL-22) Regulates Apoptosis of Paclitaxel-Resistant Non-Small Cell Lung Cancer Cells Through C-Jun N-Terminal Kinase Signaling Pathway.
Li C; Zhao X; Yang Y; Liu S; Liu Y; Li X
Med Sci Monit; 2018 May; 24():2750-2757. PubMed ID: 29723165
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of hsa_circ_0002874 promotes resistance of non-small cell lung cancer to paclitaxel by modulating miR-1273f/MDM2/p53 pathway.
Xu J; Ni L; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
Aging (Albany NY); 2021 Feb; 13(4):5986-6009. PubMed ID: 33612481
[TBL] [Abstract][Full Text] [Related]
20. Nuclear complement C3b promotes paclitaxel resistance by assembling the SIN3A/HDAC1/2 complex in non-small cell lung cancer.
Wang X; Hao Y; Chen J; Ding P; Lv X; Zhou D; Li L; Li L; Xu Y; Zhu Y; Zhang W; Chen L; Liao T; He X; Ji QH; Hu W
Cell Death Dis; 2023 Jun; 14(6):351. PubMed ID: 37291119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
